AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sandler 37th A ...

Financial Performance - License and collaboration revenue for Q3 2025 was $1,000,000, a decrease of 66.7% compared to $2,997,000 in Q3 2024[20] - Net loss for Q3 2025 was $10,056,000, compared to a net loss of $16,675,000 in Q3 2024, indicating a 39.5% improvement[20] - The company reported a comprehensive loss of $10,054,000 for Q3 2025, compared to a comprehensive loss of $16,618,000 in Q3 2024, showing a 39.5% reduction[20] - For the nine months ended September 30, 2025, the net loss was $36.2 million, a decrease from a net loss of $56.7 million in the same period of 2024, representing a 36% improvement[26] - Net loss for the three months ended September 30, 2025, was $10.1 million, a decrease of $6.6 million or 39.7% compared to a net loss of $16.7 million for the same period in 2024[150] - For the nine months ended September 30, 2025, the net loss was $36.2 million compared to $56.7 million for the same period in 2024, indicating a reduction in losses[133] Revenue and Expenses - Research and development expenses for the nine months ended September 30, 2025, were $26,218,000, down 49.5% from $51,816,000 in the same period of 2024[20] - Research and development expenses for the three months ended September 30, 2025, totaled $7,618 million, a decrease of 53.3% from $16,313 million in the same period of 2024[119] - General and administrative expenses decreased by $0.5 million, or 11.0%, to $4.1 million for the three months ended September 30, 2025, from $4.6 million for the same period in 2024[153] - General and administrative expenses for the nine months ended September 30, 2025, decreased by $1.9 million, or 12.9%, to $12.9 million from $14.8 million for the same period in 2024[158] - For the nine months ended September 30, 2025, license and collaboration revenue decreased by $4.7 million, or 82.5%, to $1.0 million from $5.7 million for the same period in 2024[156] Assets and Liabilities - Total assets increased to $100,333,000 as of September 30, 2025, up from $91,049,000 at December 31, 2024, representing a 10.3% growth[18] - Total stockholders' equity increased to $93,240,000 as of September 30, 2025, up from $79,626,000 at December 31, 2024, reflecting a 17.1% increase[18] - The company’s total liabilities decreased to $7,093,000 as of September 30, 2025, down from $11,423,000 at December 31, 2024, a reduction of 38.1%[18] - Cash and cash equivalents decreased to $42,548,000 as of September 30, 2025, down from $57,387,000 at December 31, 2024, a decline of 25.8%[18] - The company reported cash and cash equivalents of $42.5 million as of September 30, 2025, down from $43.8 million at the end of 2024[26] - The company has an accumulated deficit of $417.9 million as of September 30, 2025, highlighting ongoing financial challenges[28] Cash Flow - Cash flows from operating activities resulted in a net cash used of $31.4 million for the nine months ended September 30, 2025, compared to $43.1 million in 2024, indicating a 27% reduction in cash outflow[26] - Net cash used in operating activities for the nine months ended September 30, 2025, was $31.4 million, reflecting a net loss of $36.2 million[168] - Net cash provided by financing activities for the nine months ended September 30, 2025, was $44.4 million, primarily from the sale of common stock and warrants[171] Stock and Equity - Weighted-average shares outstanding increased to 72,184,818 for Q3 2025, compared to 50,833,538 for Q3 2024, representing a 42.0% increase[20] - The Company issued 15,225,158 shares of common stock at a price of $0.8677 per share in August 2025[106] - The Company completed a public offering in December 2023, selling 4,651,163 shares of common stock at a price of $6.45 per share[105] - As of September 30, 2025, the company has 52,635,346 common stock warrants outstanding[108] - The Company recorded total stock-based compensation of $1.778 million for the three months ended September 30, 2025, a decrease of 30.5% from $2.556 million in the same period of 2024[112] Future Outlook - The company anticipates additional losses and negative cash flows until it can generate significant sales from its product candidates currently in development[28] - The company does not expect to generate significant product revenue until successful development and regulatory approval of its product candidates, which may take several years[134] - The company estimates that existing cash and cash equivalents, short-term investments, and potential future proceeds from the exercise of all outstanding common stock warrants will fund operating expenses into 2029[188] Regulatory and Compliance - The company is classified as an emerging growth company and a smaller reporting company, allowing it to take advantage of reduced reporting requirements and exemptions from certain accounting standards[179][181] - The company has identified risks related to potential disruptions at the FDA, which could negatively impact the review of regulatory submissions and overall business operations[190] - The company regained compliance with Nasdaq Listing Rule 5450(a)(1) after meeting the minimum bid price requirement of $1.00 per share[135] Miscellaneous - The global macroeconomic environment remains uncertain, potentially impacting the company's future operations due to inflation and other economic factors[29] - The One Big Beautiful Bill Act (OBBBA) was enacted, with provisions effective in 2025 and 2027, but the immediate impact is not material[79] - The company has not reported any legal proceedings or defaults upon senior securities during the reporting period[186][197] - Shattuck Labs, Inc. filed its Quarterly Report on Form 10-Q on November 6, 2025[204]

Core Viewpoint - Shattuck Labs, Inc. has initiated a Phase 1 clinical trial for its lead product candidate SL-325, a DR3 blocking antibody, and has reported financial results for Q3 2025, highlighting its strong capital position to advance clinical development [1][2][3]. Business Highlights - SL-325 is the first DR3 blocking antibody to enter clinical development, with the Phase 1 trial proceeding as planned [2]. - The company closed a private placement of approximately $103 million in August 2025, which is expected to fund operations into 2029 and support multiple clinical milestones for SL-325 [3][6]. - Recent appointments to the Board of Directors include Dan Baker, M.D., and Mona Ashiya, Ph.D., enhancing the company's leadership [4][6]. Clinical Development - The Phase 1 trial for SL-325 began with the first participants dosed in Q3 2025, focusing on safety, tolerability, immunogenicity, and pharmacokinetics [7]. - Enrollment for the single-ascending dose (SAD) and multiple-ascending dose (MAD) portions is expected to be completed by Q2 2026, with initial results anticipated by the same timeframe [7]. - The company is also developing preclinical DR3-based bispecific antibodies aimed at treating inflammatory bowel disease (IBD) [7]. Financial Results - As of September 30, 2025, cash and cash equivalents were approximately $86.1 million, down from $90.1 million a year earlier [10][14]. - Research and Development (R&D) expenses for Q3 2025 were $7.6 million, a decrease from $16.3 million in Q3 2024 [14]. - The net loss for Q3 2025 was $10.1 million, or $0.14 per share, compared to a net loss of $16.6 million, or $0.33 per share, in the same quarter of the previous year [14][21].

1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on our estimates and assumptions. All statements, other than statements of historical facts included in this presentation, are forward-looking statements, including statements concerning: our plans, objectives, goals, strategies or intentions relating to products and markets; whether the commo ...

Core Insights - The discussion focuses on the UEGW conference in Berlin, highlighting significant updates in the Inflammatory Bowel Disease (IBD) sector [1]. Group 1: Conference Overview - The UEGW conference was described as exciting, with numerous updates relevant to the IBD space [1]. - The session is part of the Wedbush Rewind series, aimed at reviewing key highlights from industry conferences [1]. Group 2: Participants - Key participants include David Nierengarten, Managing Director of the Healthcare Equity Research team at Wedbush, Dr. Marla Dubinsky from Mount Sinai, David De Vries M. Phil, CEO of Tr1X Bio, and Taylor Schreiber, MD, PhD, CEO of Shattuck Labs [2]. - The format encourages audience participation through a Q&A session, enhancing engagement during the discussion [3].

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - The Zacks Momentum Style Score helps investors identify stocks with strong momentum, addressing the challenges of defining momentum [2] Company Overview: Shattuck Labs, Inc. (STTK) - Shattuck Labs, Inc. currently holds a Momentum Style Score of B, indicating a favorable momentum outlook [3] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4] Performance Metrics - Over the past week, STTK shares increased by 3.07%, while the Zacks Medical - Biomedical and Genetics industry rose by 3.61% [6] - In a longer timeframe, STTK shares have surged by 209.66% over the past quarter and 94.44% over the last year, significantly outperforming the S&P 500, which increased by 8.11% and 19.22% respectively [7] Trading Volume - The average 20-day trading volume for STTK is 426,895 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - Recent earnings estimate revisions for STTK show positive momentum, with three estimates moving higher for the full year, raising the consensus estimate from -$0.96 to -$0.71 [10] - For the next fiscal year, three estimates have also increased, with no downward revisions noted [10] Conclusion - Considering the positive performance metrics and earnings outlook, STTK is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Summary of Shattuck Labs Conference Call Company Overview - **Company**: Shattuck Labs (NasdaqGS:STTK) - **Focus**: Development of the first in-class death receptor three (DR3) blocking antibody for inflammatory bowel disease (IBD) targeting TL1A [1][2] Core Industry Insights - **Target Mechanism**: DR3 is the sole signaling receptor for TL1A, a well-known target in IBD [2] - **Efficacy Comparison**: Targeting DR3 may provide superior efficacy compared to existing TL1A blocking antibodies due to differences in expression patterns and stability [3][10] Key Points on DR3 vs. TL1A - **Expression Levels**: - TL1A is expressed in about 8-10% of cells in actively inflamed tissue of Crohn's disease patients, while DR3 is expressed in 18-20% of those cells [5][6] - DR3 shows broader and more stable expression, making it a more reliable target [6][10] - **Immunogenicity**: - TL1A blocking antibodies have shown high rates of anti-drug antibody formation (over 65% in some cases), leading to accelerated clearance and loss of response [18][19] - DR3 does not generate immune complexes, potentially reducing immunogenicity [20] Development of SL-325 - **Antibody Characteristics**: SL-325 is a high-affinity human DR3 blocking antibody with no Fc gamma receptor binding activity, minimizing the risk of residual agonism [22][24] - **Clinical Development Timeline**: Phase one study is expected to complete in the first half of next year, with plans to move into multiple placebo-controlled phase two trials [31] Potential Indications and Market Opportunities - **Indications for Development**: - Initial focus on IBD (Crohn's disease and ulcerative colitis) with potential expansion into other autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and asthma [32][34] - The presence of specific single nucleotide polymorphisms (SNPs) in TL1A may drive pathology in various diseases [33] - **Market Need**: There is a high unmet medical need in diseases associated with TL1A signaling, making the development of DR3 blocking antibodies potentially lucrative [35] Competitive Landscape - **Current Competitors**: No disclosed programs for DR3 antagonists are known, although other companies have attempted development but faced challenges with agonist activity [29][30] Conclusion - Shattuck Labs is positioned to advance its DR3 blocking antibody, SL-325, with a focus on addressing the limitations of existing TL1A therapies and exploring a range of autoimmune diseases where there is significant unmet medical need [39]

Core Insights - Shattuck Labs, Inc. is participating in a panel discussion at the United European Gastroenterology Week (UEGW) Conference 2025, focusing on key takeaways from the event [1] - The panel will be moderated by analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., featuring KOL Marla Dubinsky, M.D. [1] Conference Details - The panel discussion titled "Wedbush UEGW Conference 2025 Rewind" will take place on October 8, 2025, from 10:00 am to 12:00 pm EST [2] - Shattuck's CEO, Taylor Schreiber, M.D., Ph.D., will represent the company during the session [2] Product Information - SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody aimed at achieving a complete and durable blockade of the DR3/TL1A pathway [2] - Preclinical studies of SL-325 show high affinity binding and superior activity compared to TL1A antibodies, indicating potential for higher efficacy and lower immunogenicity [2] - SL-325 is currently undergoing a Phase 1 clinical trial [2] Company Overview - Shattuck Labs, Inc. specializes in developing treatments for inflammatory and immune-mediated diseases, with a focus on inflammatory bowel disease (IBD) [3] - The company leverages its expertise in protein engineering to develop novel TNF receptor therapeutics, with SL-325 being its lead program [3] - Shattuck Labs operates offices in Austin, Texas, and Durham, North Carolina [3]

Core Viewpoint - Shattuck Labs, Inc. (STTK) is showing potential for a bullish breakout due to a recent "golden cross" in its moving averages, indicating a key technical support level has been reached [1][3]. Technical Analysis - STTK's 50-day simple moving average has crossed above its 200-day simple moving average, forming a "golden cross," which is a bullish signal for traders [1]. - The golden cross pattern typically follows a downtrend, indicating a reversal to an upward trend, and is considered a stronger breakout signal due to the longer time periods involved [2]. Performance Metrics - Over the past four weeks, STTK has experienced a significant rally of 149.3%, suggesting strong upward momentum [3]. - Currently, STTK holds a 2 (Buy) rating on the Zacks Rank, further supporting the bullish outlook for the stock [3]. Earnings Outlook - The earnings outlook for STTK is positive, with no earnings estimates cut and three revisions higher in the past 60 days, indicating confidence among analysts [3]. - The Zacks Consensus Estimate for STTK has also increased, reinforcing the potential for continued gains [5].

Core Viewpoint - Shattuck Labs, Inc. (STTK) has received an upgrade to Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to significant price movements based on their trading activities [3]. Business Improvement Indicators - The upgrade in earnings estimates for Shattuck Labs suggests an improvement in the company's underlying business, which is expected to drive the stock price higher [4][9]. - Over the past three months, the Zacks Consensus Estimate for Shattuck Labs has increased by 22.5%, reflecting analysts' growing confidence in the company's performance [7]. Zacks Rank System Overview - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6][8]. - Shattuck Labs' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [9].